From the Canadian Rheumatology Association (May 21, 2019):
As evidence for the benefits and risks of using biosimilars in the management of rheumatic diseases has grown rapidly, the Canadian Rheumatology Association (CRA) has updated its position statement on biosimilars accordingly. We have undertaken this initiative to ensure that you and your patients are in possession of up-to-date guidance regarding the use and potential benefits and risks of biosimilars so that informed and appropriate treatment decisions may be made.
Please click here to view the updated position statement and FAQ’s.
Note that the CIBRN Leaders will be discussing this updated position policy at the CIBRN webinar to be held Wednesday, May 21 2019. See webinar connection details here.